@article {ANG3241, author = {CELINA SU-PING ANG and MARK YIPIN SUN and DAVID FIDEL HUITZIL-MELENDEZ and JOANNE FU-LOU CHOU and MARINELA CAPANU and WILLIAM JARNAGIN and YUMAN FONG and RONALD PAUL DEMATTEO and MICHAEL D{\textquoteright}ANGELICA and PETER ALLEN and CHIN-TUNG CHEN and EILEEN MARY O{\textquoteright}REILLY and MARTIN ROSS WEISER and GHASSAN KHALED ABOU-ALFA}, title = {c-MET and HGF mRNA Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Survival}, volume = {33}, number = {8}, pages = {3241--3245}, year = {2013}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Data on the clinicopathological features and prognostic impact of c-N-Methyl-N{\textquoteright}-nitro-N-nitroso-guanidine HOS Transforming gene (c-MET) and hepatocyte growth factor (HGF) in hepatocellular carcinoma (HCC) are inconsistent. We assessed c-MET and HGF expression in 49 patients with early-stage HCC and correlated the results with disease characteristics and survival. Materials and Methods: Expression of c-MET and HGF mRNA in tumor (T) and non-tumor (NT) tissues was assessed. Results were correlated with patient characteristics and overall and recurrence-free survival. Results: Median relative tumor c-MET and HGF expressions were 3.23 (T/NT ratio 6.46) and 9.07 (T/NT ratio 0.77), respectively. c-MET and HGF were overexpressed in early-stage disease with favorable characteristics although there was no association with survival. Conclusion: Contrary to other studies, in our series increased tumor c-MET and HGF expressions were associated with favorable disease attributes but not with survival. The prognostic and therapeutic applications of this knowledge to HCC are under active investigation.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/33/8/3241}, eprint = {https://ar.iiarjournals.org/content/33/8/3241.full.pdf}, journal = {Anticancer Research} }